Our reason for being
what we love
are good at
Ikigai compounds two Japanese words: iki meaning «life» and gai meaning «result». Hence, Ikigai is a Japanese concept that means «a reason for being». The word refers to having a meaningful direction: our purpose in life.
Having a clear and defined ikigai gives satisfaction, passion, happiness, and meaning to life. At Towa our Ikigai is clear…
At Towa International, we contribute to people’s health. We are dedicated to genuine smiles
We want to be an active player in the national sustainability health systems and provide high-quality and valued medicines through our R&D center, as well as the international presence and strategic alliances, to patients around the world.
Quality, safety and efficacy of our medicines.
Health and quality of life of patients.
Sustainability of public health systems and health promotion.
Good governance and ethical and responsible practices.
Transparency and creation of valuable relationships with our stakeholders.
Reduction of the environmental impact of our activities.
We have a shared vision
As part of Towa, we are health ambassadors, starting with ourselves and our surroundings. #WeAreCommittedToHealth
We are more than 900 professionals across 4 countries: Spain, Italy, Portugal, and the United States of America.
Towa’s human team is behind the success of our high-quality products and services.
They are our key element
Real people who internalize the corporate philosophy as part of their DNA and work every day to contribute directly to the purpose of our company.
We want to be recognized for caring for people’s health, starting with our own, and for flexibility.
We want to be the company where people decide to stay because of our purpose and our well-being.
We have two axes of the value proposition to our employees and part of the culture that as Towa we want to promote.
We are going to work intensely to advance with measures in both areas so that all of us can balance our personal lives with the responsibilities of our work. This will improve the efficiency of our organization and our health and well-being.
to the World
Our Journey begins in 1951
Towa Pharmaceutical was founded in Osaka – a family run-pharmaceutical company that specializes in the manufacture of therapeutic solutions in Japan.
Towa Group contributes to people’s health by creating superior products and services.
Through our corporate activities, we aim to be a company that is valued and needed by patients, medical professionals, local communities, and others.
In 2020 Towa became international by adding the Pensa Pharma business, a well-established patent medicine platform with a commercial presence in the US and the EU and R&D and manufacturing capabilities.
Through this internationalization milestone, Towa International headquarters were established in Barcelona, Spain.
At Towa International, we work to research, develop and market generic and value-added medicines (VAM) that contribute to improving the health of patients. In turn, they allow greater availability and better management of treatments for health professionals and support the sustainability of health systems in more than 30 countries in which we operate.
Our story together
Towa Pharmaceutical was founded originally as a family-run business
Pensa originates from PPI expertise and a non-infringement formulation of Omeprazole
Contruction of Martorelles (Barcelona) manufacturing and R&D facilities
Mr. Itsuro Yoshida became the president
Creation of B2B business
Osaka Research Center and Osaka Distribution Center are constructed at Ichiban-cho, Kadoma, Osaka
Launch of Omeprazole
Towa was listed on stock exchange
Pensa Pharma Foundation
Start of the internationalisation phase. Expanded Pensa into Italy with the purchase of 20 additional products.
Built pilot plant and expanded R&D capabilities. Entered Portugal through the acquisition of toLife, adding 30 additional products to Pensa’s portfolio
Entered U.S.A with acquisition of Breckenridge. Entered Sweeden
Towa purchases Daichi Kasei Co., Ltd., and makes it subsidiary
Established Greencaps Pharmaceutical Co., Ltd. JV with Dankyo Co., Ltd.
Foundation of Towa Pharma International Holding
Expansion manufacturing facilities
Towa purchases Protosera Inc. and makes it subsidiary
Internalization process. Entering South America and Middle East though licenses
Towa purchases Sun Sho Pharmaceutical Co., Ltd. and makes it subsidiary
Towa Presence in Japan
Greencaps Pharmaceutical Co. Ltd.
Producing soft capsules for pharmaceutical products. Headquarters: Fujinomiya, Shizuoka, Japan.
Manufacturing and selling of ethical and OTC drugs. Capsules technology. Headquarters: Osaka, Japan
J- DOLPH Pharmaceutic Co. Ltd.
Manufacturing and selling of ethical drugs. Headquarters: Koka, Shiga, Japan.
Daiichi Kasei, Co., Ltd.
R&D and manufacturing of APIs and intermediates. Headquarters: Fukusaki, Kanzaki, Hyogo, Japan.
T Square Solutions Co., Ltd.
Providing healthcare-related IT services. Headquarters: Moriguchi, Osaka.
Disease risk testing service business and research and development of diagnostic drugs. Headquarters: Osaka, Osaka
We ensure to cover all the phases
of our value chain in our products
Active Pharmaceutical Ingredients (APIs)
Research and Development of Finished Dosage Forms (FDFs)
Regulatory Affairs and Quality Control
Manufacturing and Stable product supply
Marketing and distribution
generic medicines company ranking in Japan
tablets per year
As one of our challenges, we aim for creating a future that provides full coverage of medical expenses to care for pre-symptomatic disease and prevention for society with a long and healthy life expectancy.
In line with our vision of contributing to people’s health, we will work to create new health-related businesses that are suited to the new medical system, while acquiring new techniques and integrating them with completely new knowledge and technologies.
Specifically, we will help build an infrastructure to create ideal local communities, and contribute to extending healthy life expectancy by providing necessary health promotion services to people in need of them.
Among our key measures, we will be launching testing services for determining disease risks, expanding the KENTO Healthcare Science Center, which opened in 2019 to conduct joint research with the National Cerebral and Cardiovascular Center to extend healthy life expectancy, and collecting/ utilizing information obtained from testing to provide appropriate health-related services.
Building a foundation for extending healthy life expectancy by utilizing key data
Contributing to the Comprehensive Community Care System
Further enhancing the lineup of products and services to maintain and improve health
Entering disease risk testing service business
Creating synergies with existing businesses